Search Results
Your search for ,WHo matches 20197 pages
Showing 1651 - 1700Cancer Care Disparities Among Patients With Early-Onset Colorectal Cancer
Investigators have found that Black patients with early-onset colorectal cancer in the United States may receive worse and less timely, guideline-concordant care than White patients, according to a recent study published by Nogueira et al in the Journal of Clinical Oncology. Background “Colorectal...
Osimertinib With or Without Chemotherapy in EGFR-Mutant Advanced NSCLC
As reported in The New England Journal of Medicine by Planchard et al, the phase III FLAURA2 trial has shown superior progression-free survival with osimertinib plus platinum-based chemotherapy vs osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...
Effect of Bendamustine Prior to Apheresis on Outcomes in Large B-Cell Lymphoma Treated With CAR T-Cell Therapy
In a retrospective study reported in the Journal of Clinical Oncology, Iacoboni et al found that preapheresis bendamustine exposure was associated with poorer outcomes among patients with relapsed or refractory large B-cell lymphoma receiving CD19-targeted chimeric antigen receptor (CAR) T-cell...
Patients With Lower-Extremity Lymphedema May Face Increased Risk of Skin Cancer
The risk of developing skin cancer may be twofold for patients with lymphedema, according to a recent study published by Anand et al in Mayo Clinic Proceedings. The new findings may contribute to growing information linking lymphedema to localized changes in immunity and a predisposition for...
Vitamin D Supplements May Help Reduce Chemotherapy-Induced Peripheral Neuropathy
Investigators have found that patients with breast cancer who have insufficient levels of vitamin D prior to initiating treatment with paclitaxel may be more likely to experience peripheral neuropathy, according to a recent study published by Chen et al in JNCCN–Journal of the National...
FDA Approves First Treatment for Patients With Rare Congenital Blood Disorder
On November 9, the U.S. Food and Drug Administration (FDA) approved ADAMTS13, recombinant-krhn (Adzynma), the first genetically engineered protein product indicated for prophylactic or on-demand enzyme replacement therapy in adult and pediatric patients with congenital thrombotic thrombocytopenic...
FDA Amends Pembrolizumab’s Gastric Cancer Indication
On November 7, the U.S. Food and Drug Administration (FDA) revised the existing indication of pembrolizumab (Keytruda) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic...
FDA Approves Fruquintinib for Refractory Metastatic Colorectal Cancer
On November 8, the U.S. Food and Drug Administration (FDA) approved fruquintinib (Fruzaqla) for adult patients with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF therapy; and—if their disease is RAS wild-type and it...
Screening for Lung Cancer: Much Work Remains to Be Done
Remarkable progress has been made in the treatment of lung cancer in the past 10 to 15 years; it is therefore not surprising that lung cancer mortality in the United States is declining consistently, at the rate of 2% to 4% annually in recent years. Long-term survival is possible even for patients...
How ASCO Is Tackling the Need to Improve Workforce Diversity and the Looming Oncology Workforce Shortage
On June 29, 2023, the U.S. Supreme Court, in a 6-to-3 decision, essentially overturned affirmative action in college admissions, which had allowed, since 1978, for colleges and universities to consider race as a factor in student admissions.1 The ruling will impact enrollment decisions at public...
Results of PACIFIC Trial Being Replicated in Real-World Settings
Real-world outcomes often fall short of those achieved in clinical trials, but this is apparently not so for patients receiving chemoradiotherapy plus consolidation with durvalumab in unresectable stage III non–small cell lung cancer (NSCLC). The robust results achieved in the phase III PACIFIC...
Association Urges Congress to Prioritize Childhood Cancer Funding, Research
In honor of Childhood Cancer Awareness Month, the Association for Clinical Oncology (ASCO) joined with 25 stakeholders for a series of advocacy activities in Washington, DC, during the week of September 18. During meetings with lawmakers on September 20, ASCO and the Alliance for Childhood Cancer...
Having Colorectal Cancer at 32 Changed the Trajectory of My Life
I’ve been contending with health issues since I was 12, when I was diagnosed with Crohn’s disease. As I began my early 30s, I was feeling the healthiest of my life. I was working out 5 days a week and attributed sudden weight loss and fatigue to weight training and high-intensity Zumba classes....
Understanding Patient Engagement in Virtual Mind-Body Therapies
Guest Editor’s Note: Virtual platforms have grown increasingly popular for health- and wellness-promoting activities. But given patients’ unique backgrounds, capabilities, interests, and goals, promoting engagement represents a complex challenge both in the context of care delivery as well as...
British Pharmacological Society Names V. Craig Jordan, DSc, PhD, Recipient of the Sir Henry Wellcome Gold Medal
In December 2023, the British Pharmacological Society will present the Sir Henry Wellcome Gold Medal to Prof. V. Craig Jordan, CMG, OBE, DSc, PhD, FMedSci, FBPhS. This is the highest award for lifetime contributions to pharmacology by the British Pharmacological Society of Great Britain. Dr. Jordan ...
Novel Antibody-Drug Conjugate Shows Potential in Treating CLDN18.2-Positive Gastric and GEJ Cancers
A first-in-class, claudin 18.2 (CLDN18.2)-targeted antibody-drug conjugate may be a new treatment option for patients with advanced gastric/gastroesophageal junction (GEJ) cancers, according to data presented by Xu et al during the ASCO Plenary Series: November 2023 Session (Abstract 434420)....
Genetics of Nearby Healthy Tissue May Help Predict Lung Cancer Recurrence
Genetic information collected from healthy tissue near lung tumors may be predictive of posttreatment cancer recurrence compared with analysis of the tumors themselves, according to a novel study published by Dolgalev et al in Nature Communications. Background Lung adenocarcinomas are tumors that...
Nemtabrutinib May Provide Benefit in Patients With Relapsed Hematologic Malignancies
The BTK inhibitor nemtabrutinib may offer a new treatment option for patients with relapsed hematologic malignancies such as chronic lymphocytic leukemia and non-Hodgkin lymphoma, according to a recent study published by Woyach et al in Cancer Discovery. Background Hematologic malignancies are...
Low-Dose CT Screenings Leading to Early Diagnosis May Improve Long-Term Lung Cancer Survival Rates
Diagnosing early-stage lung cancer with low-dose computed tomography (CT) screening may improve 20-year survival rates, according to a recent study published by Henschke et al in Radiology. The new findings demonstrated the significance of routine early screenings to detect tumors when they are...
Can High BMI in Youth Affect Cancer Risk Later On?
Men with overweight or obesity at age 18 years may have a higher risk of 17 different cancers later in life, according to recent research from the University of Gothenburg. The findings also describe how the youth obesity epidemic is expected to affect cancer incidence over the next 30 years. In...
Adjuvant Atezolizumab/Bevacizumab vs Active Surveillance in Resected or Ablated High-Risk Hepatocellular Carcinoma
As reported in The Lancet by Shukui Qin, MD, and colleagues, interim analysis of the phase III IMbrave050 trial has shown significantly better recurrence-free survival with adjuvant atezolizumab/bevacizumab vs active surveillance in patients who underwent curative-intent resection or ablation for...
Machine-Learning Model May Accurately Calculate Chemotherapy Success in Patients With Osteosarcoma
Researchers have developed and trained a new machine learning model to calculate percent necrosis in patients with osteosarcoma, according to a novel study published by LiBrizzi et al in the Journal of Orthopaedic Research. Background A postchemotherapy percent necrosis calculation often helps...
Novel Strategy May Improve Outcomes in Patients With Treatment-Resistant DLBCL
Researchers have found that a DNA repair–facilitating mechanism may be responsible for a tumor’s treatment resistance and could be treated with a combination of chemotherapies, according to a recent study published by Marullo et al in Cancer Research. The mechanism involves the shuttling of...
Secondary PIK3CA Mutations, Drug Resistance, and Novel PI3K Alpha Inhibitors in Breast Cancer
Researchers have discovered that resistance to PI3K-alpha inhibitors and reduced drug binding in patients with breast cancer may be driven by secondary PIK3CA mutations and so may be effectively treated with a novel class of PI3K-alpha inhibitors designed to bind to different parts of the target,...
Personalized Care May Prevent Overscreening for Colorectal Cancer in Older Patients
Researchers have found that presenting older patients with personalized information regarding the benefits and harms of colorectal cancer screenings may reduce unnecessary screenings, according to a recent study published by Saini et al in JAMA Internal Medicine. Background Colorectal cancer...
First-Line Selpercatinib vs Chemotherapy With or Without Pembrolizumab in RET Fusion–Positive NSCLC
An interim analysis of the phase III LIBRETTO-431 trial has shown significantly improved progression-free survival with first-line selpercatinib vs platinum-based chemotherapy with or without pembrolizumab in patients with RET fusion–positive advanced non–small cell lung cancer (NSCLC). The...
2023 National Youth Tobacco Survey Shows Drop in E-Cigarette Use Among High School Students
On November 2, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) released data from the 2023 National Youth Tobacco Survey (NYTS) on tobacco product use among U.S. youth. The findings—which were collected between March and June 2023 and were...
Perioperative Durvalumab in Resectable NSCLC: AEGEAN Trial
As reported in The New England Journal of Medicine by John V. Heymach, MD, PhD, and colleagues, the phase III AEGEAN trial has shown that perioperative durvalumab improved event-free survival and pathologic complete response (pCR) rate in patients with resectable non–small cell lung cancer ...
Novel Blood Test May Offer Early Cancer Detection
Researchers have developed a highly sensitive blood test capable of early detection by identifying a key protein produced by cancer cells, according to a novel study published by Taylor et al in Cancer Discovery. Background Many tumors become deadly by remaining asymptomatic until they’re too...
Immune Checkpoint Inhibition With Single-Fraction Stereotactic Radiosurgery May Not Increase Risk of Radiation Necrosis in Patients With NSCLC Brain Metastases
Researchers have explored the impact of immune checkpoint inhibition and single-fraction stereotactic radiosurgery on radiation necrosis in patients with non–small cell lung cancer (NSCLC) brain metastases, according to a novel study published by Lehrer et al in the Journal of Neuro-Oncology. Study ...
ACS Releases Updated Lung Cancer Screening Guideline
Lung cancer incidence overall has been declining in the United States since 1992 and since 2006–2007 for both men and women by 2.7% annually and 1.1%, respectively, and overall mortality rates have declined in both men and women due to smoking cessation efforts and advances in therapy and early...
FDA Approves Pembrolizumab Plus Chemotherapy for Biliary Tract Cancer
On October 31, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) to be used with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. KEYNOTE-966 Efficacy was evaluated in KEYNOTE-966...
Insurance Coverage Disruptions May Reduce Rate of Cancer Screenings
Investigators have found that U.S. adult patients with prior insurance coverage disruptions may be less likely to receive guideline-concordant and past-year cancer screenings compared with those with continuous coverage, according to new findings presented by Shi et al at the 2023 ASCO Quality Care ...
Addition of Amivantamab to Chemotherapy in First-Line Treatment of Advanced NSCLC With EGFR Exon 20 Insertions
The phase III PAPILLON study has shown that the addition of amivantamab-vmjw to chemotherapy significantly improved progression-free survival in the first-line treatment of advanced non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions. The findings were presented at the European Society...
Association of Germline EGFR Mutations With Familial Lung Cancer
In the INHERIT study—reported in the Journal of Clinical Oncology—Geoffrey R. Oxnard, MD, FASCO, and colleagues identified associations between germline EGFR mutations and familial lung cancer. As stated by the investigators, “The genomic underpinnings of inherited lung cancer risk are poorly...
Patients With Newly Diagnosed NSCLC or Melanoma May Receive Limited Documentation of Treatment Cost Discussions
Investigators have uncovered that only about 25% of patients newly diagnosed with advanced cancer have documented physician discussions about the costs of care, which may make it more difficult to identify patient needs and track the outcomes of referrals for assistance, according to new findings...
Role of Crowdfunding Campaigns in Covering Medical Expenses for Cancer Survivors
Investigators have discovered that cancer survivors in the United States may be increasingly utilizing crowdfunding campaigns like GoFundMe to help cover the costs of medical and other basic household expenses, according to new findings presented by Zheng et al and Yu et al at the 2023 ASCO Quality ...
Cardiovascular Disease and Cancer: A Reciprocal Relationship?
More attention is being paid to the topic of cardio-oncology, where the focus is on patients with cancer who may be at risk for developing cardiovascular diseases as a result of anticancer treatments. However, a less well-known but related clinical area is now garnering some interest. Referred to...
Expert Point of View: Rohann J.M. Correa, MD, PhD
Abstract discussant Rohann J.M. Correa, MD, PhD, a radiation oncologist at London Health Sciences Centre and Assistant Professor at Western University, Canada, shared his insights on this landmark clinical trial for the treatment of kidney cancers. “FASTRACK II represents an important milestone,...
Stereotactic Body Radiation Therapy Demonstrates ‘Exceptional Control’ in Primary Renal Cell Carcinoma
Although surgery remains the standard of care for primary renal cell carcinoma, a novel, noninvasive approach has yielded positive results that could pave the way for future treatment strategies, according to data presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual...
Expert Point of View: Neha Vapiwala, MD, FASTRO
Discussant of the PACE-B abstract, Neha Vapiwala, MD, FASTRO, acknowledged the impressive efforts of PACE investigators to elucidate the various treatment options for patients with localized prostate cancer—a challenging task because of the frequent absence of clear evidence. Dr. Vapiwala is...
PACE Trials Support Stereotactic Body Radiotherapy for Some Patients With Localized Prostate Cancer
Prostate cancer treatment just got a major boost from the PACE trials, which may have established a new standard of care in low- and favorable intermediate-risk disease, according to data presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 The results of the phase ...
Intraductal Papillary Mucinous Neoplasms: Risk of Pancreatic Cancer
In a retrospective cohort study reported in JAMA Network Open, de la Fuente et al found that the risk of pancreatic cancer in patients with Fukuoka criteria–negative intraductal papillary mucinous neoplasms (F-N IPMNs) did not differ from that in patients without IPMNs. In addition, the small...
Expert Point of View: Marina C. Garassino, MD
“CheckMate 77T shows very promising results to support the use of perioperative nivolumab in resectable NSCLC,” said formal discussant Marina C. Garassino, MD, of the University of Chicago. “In particular, the trial demonstrated that patients could achieve incredible disease control rates. These...
Perioperative Nivolumab Plus Chemotherapy Improves Event-Free Survival in Resectable Non–Small Cell Lung Cancer
A perioperative regimen of neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab achieved a statistically significant and clinically meaningful improvement in event-free survival compared with neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant...
FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma
On October 27, the U.S. Food and Drug Administration (FDA) approved toripalimab-tpzi (Loqtorz) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma. The FDA also approved toripalimab-tpzi as a single agent for...
Two New Studies Using CancerLinQ Data
Two new studies—presented by Drumheller et al and Vento et al at the 2023 ASCO Quality Care Symposium—utilized data from ASCO’s CancerLinQ® database (Abstracts 418 and 532). One study revealed deficiencies in biomarker testing and tracking in electronic health records, and the other analyzed...
Datopotamab Deruxtecan May Improve Progression-Free Survival in Patients With Metastatic NSCLC
The TROP-2–directed antibody-drug conjugate datopotamab deruxtecan may significantly improve progression-free survival in patients with metastatic non–small cell lung cancer (NSCLC), especially in patients with non–squamous cell tumors, according to new findings simultaneously published by Ahn et...
Sequential CD19- and CD22-Directed CAR T-Cell Therapy in Pediatric B-Cell ALL
In a Chinese single-center phase II study reported in The Lancet Oncology, Pan et al found that sequential CD19- and CD22-directed chimeric antigen receptor (CAR) T-cell therapy was active in pediatric patients with refractory or relapsed B-cell acute lymphocytic leukemia (ALL). Study Details In...
Enzalutamide With or Without Leuprolide and Leuprolide Alone in Biochemically Recurrent Prostate Cancer
In the phase III EMBARK trial reported in The New England Journal of Medicine, Stephen J. Freedland, MD, and colleagues found that enzalutamide/leuprolide and enzalutamide alone improved metastasis-free survival vs leuprolide alone in patients with high-risk biochemical recurrence of prostate...
